In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Tonix Pharma (TNXP – Research Report), with a price target of $6.50. The company’s shares closed yesterday at $0.46.
According to TipRanks, LeBoyer is an analyst with an average return of -1.9% and a 26.71% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, Ayala Pharmaceuticals, and Tonix Pharma.
Currently, the analyst consensus on Tonix Pharma is a Moderate Buy with an average price target of $6.50.
See Insiders’ Hot Stocks on TipRanks >>
Based on Tonix Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $23.14 million. In comparison, last year the company had a GAAP net loss of $23.55 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.
Read More on TNXP:
- Tonix Pharmaceuticals to Present at the 2022 BioFuture Conference
- Tonix Pharmaceuticals announces pricing of $15M private placement
- Tonix Pharmaceuticals Announces Pricing of $15 Million Private Placement of Convertible Redeemable Preferred Stock
- Tonix Pharmaceuticals to Present at the 2022 ThinkEquity Conference
- Tonix Pharmaceuticals to Participate in the 2022 BIO-Europe Conference
